newsfilter
← Latest News
PR Newswire·

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical...